Trial Profile

A Phase 1, Open-Label Study of ABSK121-NX to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 121 (Primary)
Indications Carcinoma; Cholangiocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions
Sponsors Abbisko Therapeutics

Most Recent Events

19 Jun 2023 Status changed from not yet recruiting to recruiting.
19 Jun 2023 Planned initiation date changed from 15 Dec 2022 to 30 Jun 2023.
22 Feb 2023 According to an Abbisko Therapeutics media release, the company also received IND approval from US FDA recently for this program.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com